Neopharma buys plant in Japan, will build one in the Middle East

With its purchase of a 65% stake in Japan's Cosmo ALA, UAE-based Neopharma picked up this plant in Japan.

United Arab Emirates-based drugmaker Neopharma is continuing expansion of its manufacturing footprint with plans to build a $100 million plant in Abu Dhabi just weeks after committing to spend more than twice that for manufacturing plant and development rights to a diabetes treatment in Japan.

Neopharma has acquired a second site in the Khalifa Industrial Zone where it already has a facility, B.R. Shetty told Gulf News. Shetty owns controlling interest in the company. Combined, the two facilities will occupy about 160,000 square meters (1.7 million square feet) of space.

The plans for expansion in Abu Dhabi follow the company's May announcement that it would pay Dhs880 million ($240 million) for a 65% stake in Japan’s Cosmo ALA (now known as Neo ALA) from Cosmo Energy. With that deal, it got rights to develop NatuALA, which it says is a dietary supplement to decrease glucose levels in patients with type 2 diabetes.

Neopharma says it will spend about $140 million on clinical trials in hopes of getting approval for the drug in the U.S., Japan, U.K. and Bahrain. The investment included about $26 million in a plant in Japan to produce the drug if approved.

Suggested Articles

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.

GBA offers Brexit escape, Merck and Just - Evotech to share production space, GSK ointment line in Bangladesh may reopen and more news of note.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.